STM publisher Elsevier has announced that Reaxys Medicinal Chemistry now offers the world's largest medicinal chemistry database. Reaxys Medicinal Chemistry enables researchers to quickly and confidently identify the most promising compounds to take forward in the drug discovery process by covering critical areas for medicinal chemistry research, including in vivo animal studies, in vitro efficacy, drug pharmacokinetics and toxicity data.
The Reaxys Medicinal Chemistry database contains 25 million bioactivity data points, making it the largest such dataset, with corresponding bioassays on 5.1 million unique substances compiled from 320,000 medicinal chemistry publications and patents, fully indexed and normalized.
Users who subscribe to both Reaxys and Reaxys Medicinal Chemistry will have a comprehensive view of the most relevant bioactivity data and be able to explore the structures and physiochemical properties of other known compounds, via a single integrated interface. With access to the automatic synthesis pathway generator, users can immediately start to work on selected substances. This will facilitate workflows from lead identification to compound synthesis and enable scientists to generate new drug ideas by exploring the chemical space of new compounds.
Additional new features include flexible search options; heatmap view; and improved sharing and integration.
Reaxys Medicinal Chemistry customers upgraded to the latest version on May 11th.
